Registration is required for this session:
ATA/Endocrine Society Members: $149
ATA/Endocrine Society In-Training Members: $29
Register now for this exciting program to hear the most recent recommendations from the interdisciplinary international guidelines task forces. ATA Satellite Symposium registration is available as part of the Endocrine Society 2016 Annual Meeting at https://www.endocrine.org/endo-2016/registration. Please complete the online registration process or click here to complete the Endocrine Society paper registration form. The ATA satellite program is listed on the top right of page 2 of this form.
2016 ATA Guidelines: Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
Chair: Douglas Ross, MD, Massachusetts General Hospital
Numerous studies since the publication of the 2011 guidelines have addressed the diagnosis and management of thyrotoxic patients. The ATA has developed new and updated evidence-based recommendations to guide the clinical assessment and management of patients with hyperthyroidism and other causes of thyrotoxicosis. Task force members will give special focus to:
- New paradigms for establishing the etiology of thyrotoxicosis
- Updated evidence for choosing treatment options for hyperthyroidism
- Expanded coverage of less common causes of thyrotoxicosis
2016 ATA Guidelines: Thyroid Disease During Pregnancy
Chairs: Elizabeth Pearce, MD, Boston University and Erik Alexander, MD, Brigham and Women’s Hospital.
Thyroid disease is common in pregnant women. The diagnosis and treatment of thyroid dysfunction in pregnancy provides unique challenges. A large amount of new information and evidence grading processes has become available since the 2011 guidelines prompting the ATA to develop new and updated evidence-based recommendations to assist in the clinical management of pregnant patients with thyroid disease. Task force members will give special focus to:
- New definitions and treatment paradigms for hypothyroidism in pregnancy
- Treatment of hyperthyroidism in pregnant women
- Screening for thyroid dysfunction in pregnancy
JAS: Member of the Data Monitoring Committee of the Medullary Thyroid Cancer Registry, funded by Astra Zeneca, NovoNordisk, GlaxoSmithKline, and Eli Lilly., Member of the Data Monitoring Committee of the Medullary Thyroid Cancer Registry.